EcoDrugPlus

Endothelin Converting Enzyme 1

Ensembl ID : ENSPNAG00000014942
Gene Symbol: ECE1
3 Cross references
230 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSPNAG00000025771
Gene Symbol: EDNRB
3 Cross references
196 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSPNAG00000017892
Gene Symbol: EZH2
3 Cross references
238 Possible Orthologues:

Epidermal Growth Factor Receptor

Ensembl ID : ENSPNAG00000012443
Gene Symbol: EGFR
3 Cross references
212 Possible Orthologues:

Epidermal Growth Factor Receptor-Like

Ensembl ID : ENSPNAG00000001392
Gene Symbol: LOC108443684
2 Cross references
215 Possible Orthologues:

Equilibrative Nucleoside Transporter 1-Like

Ensembl ID : ENSPNAG00000008874
Gene Symbol: LOC108430281
3 Cross references
209 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSPNAG00000009391
Gene Symbol: ERBB2
3 Cross references
199 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSPNAG00000009388
Gene Symbol: ERBB3
3 Cross references
211 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSPNAG00000022493
Gene Symbol: ERBB4
3 Cross references
230 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSPNAG00000013421
Gene Symbol: ERBB4
3 Cross references
11 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSPNAG00000006075
Gene Symbol: ERBB4
3 Cross references
230 Possible Orthologues:

Estrogen Receptor Beta-Like

Ensembl ID : ENSPNAG00000014441
Gene Symbol: LOC108443508
3 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).